There is no substitute for diligence.
Tor Gronborg is a partner in Robbins Geller Rudman & Dowd LLP’s San Diego office and a member of the Firm’s Management Committee. He often lectures on topics such as the Federal Rules of Civil Procedure and electronic discovery. Tor has served as lead or co-lead counsel in numerous securities fraud cases that have collectively recovered $3 billion for investors. Most recently, Tor and a team of Robbins Geller attorneys obtained a $1.21 billion settlement in In re Valeant Pharms. Int’l, Inc. Sec. Litig., a case that Vanity Fair reported as “the corporate scandal of its era” that had raised “fundamental questions about the functioning of our health-care system, the nature of modern markets, and the slippery slope of ethical rationalizations.” This is the largest securities class action settlement against a pharmaceutical manufacturer and the ninth largest ever.
In addition to Valeant, Tor’s work has included significant recoveries against corporations such as Cardinal Health ($600 million), Motorola ($200 million), Duke Energy ($146.25 million), Sprint Nextel Corp. ($131 million), Prison Realty ($104 million), CIT Group ($75 million), Wyeth ($67.5 million), and Intercept Pharmaceuticals ($55 million), to name a few. Tor was also a member of the Firm’s trial team in Hsu v. Puma Biotechnology, Inc., No. SACV15-0865 (C.D. Cal.), a securities fraud class action that resulted in a verdict in favor of investors after a two-week jury trial.
On three separate occasions, Tor’s pleadings have been upheld by the federal Courts of Appeals (Broudo v. Dura Pharms., Inc., 339 F.3d 933 (9th Cir. 2003), rev’d on other grounds, 544 U.S. 336 (2005); In re Daou Sys., 411 F.3d 1006 (9th Cir. 2005); Staehr v. Hartford Fin. Servs. Grp., 547 F.3d 406 (2d Cir. 2008)). He has also been responsible for a number of significant rulings, including In re Sanofi-Aventis Sec. Litig., 293 F.R.D. 449 (S.D.N.Y. 2013); Silverman v. Motorola, Inc., 798 F. Supp. 2d 954 (N.D. Ill. 2011); Roth v. Aon Corp., No. 04-C-6835, 2008 U.S. Dist. LEXIS 18471 (N.D. Ill. Mar. 7, 2008); In re Cardinal Health, Inc. Sec. Litigs., 426 F. Supp. 2d 688 (S.D. Ohio 2006); and In re Dura Pharms., Inc. Sec. Litig., 452 F. Supp. 2d 1005 (S.D. Cal. 2006).
Tor has been named a Plaintiffs’ Lawyer Trailblazer by The National Law Journal, as well as a Super Lawyer by Super Lawyers Magazine for the last nine consecutive years. He has also been named a Leading Plaintiff Financial Lawyer by Lawdragon and a Best Lawyer in America by Best Lawyers®.
He earned his Bachelor of Arts degree from the University of California, Santa Barbara, and his Juris Doctor degree from the University of California, Berkeley, where he was a member of the Moot Court Board.
- Best Lawyer in America, Best Lawyers®, 2022
- Leading Plaintiff Financial Lawyer, Lawdragon, 2019-2021
- Super Lawyer, Super Lawyers Magazine, 2013-2021
- Plaintiffs’ Lawyer Trailblazer, The National Law Journal, 2019
University of California at Berkeley, Boalt Hall, J.D., 1995
- Member, Moot Court Board
University of Lancaster, United Kingdom, 1992
- Graduate work in International Relations and Strategic Studies
- Rotary International Fellowship
University of California at Santa Barbara, B.A., 1991
- Recipient, AFL-CIO History Scholarship
- United States Courts of Appeals for the Second, Seventh and Ninth Circuits
- United States District Courts for the Northern, Central and Southern Districts of California
- United States District Court for the District of Colorado
- September 28, 2021
- Litigators of the Week: Motley Rice and Robbins Geller Land an $809M Securities Settlement From TwitterSeptember 24, 2021
- On the Eve of Jury Trial, Twitter Pays $809 million in Securities Fraud Case Prosecuted by Robbins GellerSeptember 20, 2021
- August 19, 2021
- February 17, 2021
- Robbins Geller Rudman & Dowd LLP Announces Jury Verdict Finding Puma Biotechnology and CEO Alan Auerbach Committed Securities Fraud Results in Damages Three to Six Times Higher Than the Company ClaimedSeptember 8, 2020
- August 25, 2020
- July 31, 2020
- Robbins Geller Rudman & Dowd LLP Announces Claims Process Now Open for Class Members to Claim Full Monetary Damages Against Puma Biotechnology, Inc. and Alan H. Auerbach for Federal Securities Fraud ViolationsSeptember 30, 2019
- Robbins Geller Rudman & Dowd LLP Announces Plaintiff’s Verdict in Securities Class Action Trial Against Puma Biotechnology, Inc. and Its Ceo, Alan H. AuerbachFebruary 4, 2019
- April 19, 2017
- November 3, 2015
- August 12, 2015
- March 31, 2015
- January 17, 2015
- Robbins Geller Rudman & Dowd LLP Announces Opening of Chicago Office and Recovery of $200 Million for Motorola ShareholdersFebruary 2, 2012
- December 14, 2011